Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

ClinicalTrials.gov ID: NCT00748189

Public ClinicalTrials.gov record NCT00748189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.

Study identification

NCT ID
NCT00748189
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
447 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2008
Primary completion
Mar 19, 2013
Completion
May 16, 2018
Last update posted
Jun 24, 2019

2008 – 2018

United States locations

U.S. sites
30
U.S. states
11
U.S. cities
28
Facility City State ZIP Site status
Novartis Investigative Site Sedona Arizona 86336
Novartis Investigative Site Tucson Arizona 85704
Novartis Investigative Site Murrieta California 92562
Novartis Investigative Site Aurora Colorado 80012
Novartis Investigative Site Denver Colorado 80204
Novartis Investigative Site Boca Raton Florida 33486
Novartis Investigative Site New Port Richey Florida 34655
Novartis Investigative Site Ocala Florida 34471
Novartis Investigative Site Ocoee Florida 34761
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigative Site Chicago Illinois 60612
Novartis Investigative Site Indianapolis Indiana 46227
Novartis Investigative Site Lee's Summit Missouri 64064
Novartis Investigative Site Raleigh North Carolina 27607
Novartis Investigative Site Abilene Texas 79606-5208
Novartis Investigative Site Arlington Texas 76014
Novartis Investigative Site Austin Texas 78731
Novartis Investigative Site Dallas Texas 75230
Novartis Investigative Site Dallas Texas 75231
Novartis Investigative Site Fort Worth Texas 76104
Novartis Investigative Site Midland Texas 79701
Novartis Investigative Site Odessa Texas 79761
Novartis Investigative Site San Antonio Texas 78217
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site Tyler Texas 75702
Novartis Investigative Site Waco Texas 76712
Novartis Investigative Site Webster Texas 77598-4420
Novartis Investigative Site Seattle Washington 98133
Novartis Investigative Site Vancouver Washington 98684
Novartis Investigative Site Yakima Washington 98902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 124 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00748189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00748189 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →